Topic:

Virology and viral infections (non-hiV)

Abstract No.:

ISE.409

Title:

Role of race for response to antiviral therapy of chronic hepatitis C

Author(s):

L. Orlova¹, I. Malov¹, S. Makarova²; ¹Irkutsk State Medical University, Department of Infectious Diseases, Irkutsk/RU, ²Irkutsk Regional Hospital of Infectious Diseases, department №5, Irkutsk/RU

Abstract:

Background: Based on multicentral clinical researches it was observed the different influence the races on the effectiveness of antiviral therapy. In some researches Asians showed better the effectiveness of antiviral therapy versus white. The aim of our research – study of significance the race as predictor of sustained virological response (SVR) on the antiviral treatment.
Methods: One hundred fifty patients were treated by antiviral therapy, among of them were 65,3% men and 34,7% women. Average age consisted 39,12±23 years. In this population mongoloid were 46% (69 people), the rest – 81 patients (54%) were Caucasian. The Mongoloid race included Koreans – 1,5%, Chineses – 1,5%, Buryats – 8,7% and Mongolians – 88% patients. Index mass of body was normal in 69 patients, and 68 patients had IMB more than normal. In group of overweight prevailed mongoloid – 72,1%.The prevalence of genotypes virus hepatitis C was the same in the different races. The most often we observed the 1в genotype HCV, the second place – 3а genotype, the other – more rarely. The both races had more patients with middle (10⁴-10⁵ copies/ml) and high (>10⁵copies/ml) level of viremia than patients with low (< 10³ copies/ml) viremia. According to present recommendations the patients got treatment by α2-interferon (pegylated or standard) and ribavirin during 24 or 48 weeks depending on genotype. Pegylated interferon got 46,7% patients.
Results: Sustained virological response in mongoloid consisted 62,3%, in Caucasian – slightly higher 71,2% (р>0,05). At the 1 genotype SVR was 51,02% and 59,4% in mongoloid and Caucasian patients accordingly. At the non 1 genotype patients of mongoloid race had 90% SVR, and Caucasian – 81,8% (р>0,05).
Conclusion: In contrast to the literature data for evaluating the significance of race on outcome of treatment we was not received significant difference in the effectiveness of therapy in different races. The frequency of SVR in patients Mongoloid race was 62,3%, which corresponds to foreign authors, in which the frequency SVR ranged from 61% to 70,7%. However, the response rate for white according to the same authors, was only 39–45%, significantly lower than the results of our study – 71,6%.